Gritstone Oncology Announces Data on Novel Shared Tumor-Specific Neoantigens Identified by its EDGE Platform and Contained Within its SLATE Immunotherapy Portfolio News / admin November 5, 2019 Gritstone Oncology Announces Data on Novel Shared Tumor-Specific Neoantigens Identified by its EDGE Platform and Contained Within its SLATE Immunotherapy Read More »
Arcus Biosciences Announces Third Quarter 2019 Financial Results and Recent Corporate Updates Portfolio News / admin November 5, 2019 Arcus Biosciences Announces Third Quarter 2019 Financial Results and Recent Corporate Updates Read More »
A2 Biotherapeutics Emerges From Stealth Mode With $57M Series A to Develop a Pipeline of Selective Tumor Cell Therapeutics Portfolio News / admin November 5, 2019 A2 Biotherapeutics Emerges From Stealth Mode With $57M Series A to Develop a Pipeline of Selective Tumor Cell Therapeutics Read More »
RAPT Therapeutics Announces Pricing of Initial Public Offering Portfolio News / admin October 31, 2019 RAPT Therapeutics Announces Pricing of Initial Public Offering Read More »
ORIC Pharmaceuticals Presents Preclinical Data on Glucocorticoid Receptor Antagonist and CD73 Inhibitor Programs at AACR-NCI-EORTC Annual Conference Portfolio News / admin October 28, 2019 ORIC Pharmaceuticals Presents Preclinical Data on Glucocorticoid Receptor Antagonist and CD73 Inhibitor Programs at AACR-NCI-EORTC Annual Conference Read More »
RAPT Therapeutics Announces Initiation of First-In-Human Phase 1 Study of RPT193 Portfolio News / admin October 23, 2019 RAPT Therapeutics Announces Initiation of First-In-Human Phase 1 Study of RPT193 Read More »
Plexium Launches with $28 Million in Series A Financing Portfolio News / admin October 17, 2019 Plexium Launches with $28 Million in Series A Financing Read More »
NGM Bio Announces Positive Interim Results from Ongoing 24-Week Phase 2 Study Evaluating Aldafermin (NGM282) in Patients with NASH Portfolio News / admin October 7, 2019 NGM Bio Announces Positive Interim Results from Ongoing 24-Week Phase 2 Study Evaluating Aldafermin (NGM282) in Patients with NASH Read More »
Tenaya Therapeutics Closes $92 Million Series B Financing Portfolio News / admin October 3, 2019 Tenaya Therapeutics Closes $92 Million Series B Financing Read More »
NGM Bio Announces Multiple Aldafermin (NGM282) Poster Presentations at Upcoming AASLD’s The Liver Meeting Portfolio News / admin October 3, 2019 NGM Bio Announces Multiple Aldafermin (NGM282) Poster Presentations at Upcoming AASLD’s The Liver Meeting Read More »